-

VALERIO THERAPEUTICS: List of the Board Members Positions Held in Other Companies as of March 19, 2025

PARIS--(BUSINESS WIRE)--Regulatory News:

VALERIO THERAPEUTICS (Paris:ALVIO):

 Name of Director

Other offices and functions

 

Julien MIARA

Chief Executive Officer and Director

 

  • Managing Director at Invus
  • Director of Sensorion
  • Director of Versity

 

Jacques MALLET

Director and Chairman of the Board

 

  • Chairman of Gamma-X Corporate Advisory
  • Director of Technoflex
  • Director of the Fournier Majoie Foundation

 

FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA

Director

 

  • Manager of SARL Financière de la Montagne
  • Manager of SCI Fleurus Immobilier
  • Chairman of SAS Dragon 8
  • Managing partner of SC Financière des Associés
  • Chairman of the Supervisory Board of SCA Chevrillon & Associés
  • Manager of EARL Ferme de Bissy
  • Managing partner of SC Valois
  • Co-manager of SC Aster
  • Managing partner of SCI du Chardonnet

 

Bryan GIRAUDO

Director

 

  • Chief Operating Officer and Chief Financial Officer of Gossamer Bio Inc
  • Director of Protagonist Therapeutics
  • Senior Managing Director at Leerink Partners

Antoine BAROUKY

Chief Operating Officer and Director

  • Chairman & CEO of MAAsiRNA
  • Chairman & CEO of AB Global Strategy
  • Venture Partner at Invus

 

Shefali AGARWAL

Director

 

  • Member of the Board of Directors of ITB Med (unlisted)
  • Member of the Board of Directors of Gritstone Bio (Nasdaq: GTRS)
  • Member of the Board of Directors of Fate Therapeutics (Nasdaq: FATE)

VALERIO THERAPEUTICS
Société anonyme à conseil d’administration au capital social de 21.610.998,20 euros
Siège social : 49 boulevard du Général Martial Valin, 75015 Paris 410 910 095 R.C.S. Paris

Contacts

VALERIO THERAPEUTICS

VALERIO THERAPEUTICS

BOURSE:ALVIO
Release Versions
English

Contacts

VALERIO THERAPEUTICS

More News From VALERIO THERAPEUTICS

Valerio Therapeutics: Report of the Board of Directors

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (Paris:ALVIO): Ladies and Gentlemen, We have convened this General Meeting in order to submit for your approval decisions which fall within the remit of both the Ordinary and Extraordinary General Meetings. You are therefore asked to vote on the following agenda: Agenda for the Ordinary General Meeting First resolution: Dismissal of a member of the Board of Directors (Shefali Agarwal) Second resolution: Ratification of the co-optatio...

Valerio Therapeutics Announces the Termination of the Liquidity Contract Entered Into on 29 October 2018 With KEPLER CHEUVREUX

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the ‘Company’) announces that it has terminated the liquidity agreement entered into on 29 October 2018 with KEPLER CHEUVREUX (the ‘Agreement’). The termination was effective on 19 February 2025. The termination of the Agreement was decided as part of the savings made by the Company given its cash position. The Company does not intend to enter into another liquidity contract at this stage. It shou...

Valerio Therapeutics Announces Strategic Refocus

PARIS--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) today announced a strategic decision to discontinue all clinical trials and associated activities, including the ongoing VIO-01 trial. This shift was decided by the board of directors in the context of the financing challenges of the Company. The Company’s cash position should enable it to finance its refocused business other the next three months. In the meantime, in addition to the reduction of i...
Back to Newsroom